ATE342728T1 - Zubereitung zur behandlung von einer neurologischen erkrankung - Google Patents
Zubereitung zur behandlung von einer neurologischen erkrankungInfo
- Publication number
- ATE342728T1 ATE342728T1 AT00918991T AT00918991T ATE342728T1 AT E342728 T1 ATE342728 T1 AT E342728T1 AT 00918991 T AT00918991 T AT 00918991T AT 00918991 T AT00918991 T AT 00918991T AT E342728 T1 ATE342728 T1 AT E342728T1
- Authority
- AT
- Austria
- Prior art keywords
- preparation
- treatment
- neurological disease
- rar22
- agonist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1783—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- High Energy & Nuclear Physics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9907461.9A GB9907461D0 (en) | 1999-03-31 | 1999-03-31 | Neurite regeneration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE342728T1 true ATE342728T1 (de) | 2006-11-15 |
Family
ID=10850746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00918991T ATE342728T1 (de) | 1999-03-31 | 2000-03-30 | Zubereitung zur behandlung von einer neurologischen erkrankung |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20070054961A1 (enExample) |
| EP (2) | EP1180039B1 (enExample) |
| JP (1) | JP2002540164A (enExample) |
| KR (1) | KR20010104401A (enExample) |
| CN (1) | CN100350970C (enExample) |
| AT (1) | ATE342728T1 (enExample) |
| AU (1) | AU770394B2 (enExample) |
| CA (1) | CA2369009A1 (enExample) |
| DE (1) | DE60031396T2 (enExample) |
| GB (2) | GB9907461D0 (enExample) |
| WO (1) | WO2000057900A2 (enExample) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001244354A1 (en) * | 2000-03-30 | 2001-10-15 | Oxford Biomedica (Uk) Limited | Retinoic acid receptor beta-2, its antagonists, and gene therapy vectors for thetreatment of neurological disorders |
| GB0103998D0 (en) * | 2001-02-19 | 2001-04-04 | King S College London | Method |
| EP1592867B1 (en) | 2003-02-11 | 2016-11-23 | Statoil ASA | Efficient combined cycle power plant with co2 capture and a combustor arrangement with separate flows |
| SG10201707569YA (en) | 2012-12-12 | 2017-10-30 | Broad Inst Inc | Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Therapeutic Applications |
| EP2931899A1 (en) | 2012-12-12 | 2015-10-21 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof |
| KR20250012194A (ko) | 2013-06-17 | 2025-01-23 | 더 브로드 인스티튜트, 인코퍼레이티드 | 바이러스 구성성분을 사용하여 장애 및 질환을 표적화하기 위한 crispr-cas 시스템 및 조성물의 전달, 용도 및 치료 적용 |
| SG11201510327TA (en) | 2013-06-17 | 2016-01-28 | Broad Inst Inc | Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells |
| JP6738728B2 (ja) | 2013-06-17 | 2020-08-19 | ザ・ブロード・インスティテュート・インコーポレイテッド | 肝臓ターゲティングおよび治療のためのＣＲＩＳＰＲ−Ｃａｓ系、ベクターおよび組成物の送達および使用 |
| CN105899658B (zh) | 2013-12-12 | 2020-02-18 | 布罗德研究所有限公司 | 针对hbv和病毒性疾病以及障碍的crispr-cas系统和组合物的递送、用途和治疗应用 |
| KR20160097338A (ko) | 2013-12-12 | 2016-08-17 | 더 브로드 인스티튜트, 인코퍼레이티드 | 뉴클레오티드 반복 장애에서의 ｃｒｉｓｐｒ-ｃａｓ 시스템의 조성물 및 방법 및 용도 |
| JP6793547B2 (ja) | 2013-12-12 | 2020-12-02 | ザ・ブロード・インスティテュート・インコーポレイテッド | 最適化機能ＣＲＩＳＰＲ−Ｃａｓ系による配列操作のための系、方法および組成物 |
| CN111206032B (zh) | 2013-12-12 | 2024-07-19 | 布罗德研究所有限公司 | 用于基因组编辑的crispr-cas系统和组合物的递送、用途和治疗应用 |
| WO2015089473A1 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation |
| EP3180426B1 (en) | 2014-08-17 | 2019-12-25 | The Broad Institute, Inc. | Genome editing using cas9 nickases |
| WO2016049163A2 (en) | 2014-09-24 | 2016-03-31 | The Broad Institute Inc. | Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder |
| WO2016049258A2 (en) | 2014-09-25 | 2016-03-31 | The Broad Institute Inc. | Functional screening with optimized functional crispr-cas systems |
| WO2016094880A1 (en) | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs) |
| EP3985115A1 (en) | 2014-12-12 | 2022-04-20 | The Broad Institute, Inc. | Protected guide rnas (pgrnas) |
| EP3230452B1 (en) | 2014-12-12 | 2025-06-11 | The Broad Institute, Inc. | Dead guides for crispr transcription factors |
| WO2016094874A1 (en) | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Escorted and functionalized guides for crispr-cas systems |
| CN107207488B (zh) | 2014-12-17 | 2020-11-17 | 伦敦皇家学院 | 作为视黄酸受体β(RARβ)激动剂的双环杂芳基-杂芳基-苯甲酸化合物 |
| EP3234192B1 (en) | 2014-12-19 | 2021-07-14 | The Broad Institute, Inc. | Unbiased identification of double-strand breaks and genomic rearrangement by genome-wide insert capture sequencing |
| WO2016106236A1 (en) | 2014-12-23 | 2016-06-30 | The Broad Institute Inc. | Rna-targeting system |
| WO2016106244A1 (en) | 2014-12-24 | 2016-06-30 | The Broad Institute Inc. | Crispr having or associated with destabilization domains |
| US20180355033A1 (en) | 2015-06-10 | 2018-12-13 | Dana-Farber Cancer Institute, Inc. | Antibodies, compounds and screens for identifying and treating cachexia or pre-cachexia |
| AU2016279062A1 (en) | 2015-06-18 | 2019-03-28 | Omar O. Abudayyeh | Novel CRISPR enzymes and systems |
| CA3012631A1 (en) | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Novel crispr enzymes and systems |
| WO2016205745A2 (en) | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Cell sorting |
| US9790490B2 (en) | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| EP3929287A3 (en) | 2015-06-18 | 2022-04-13 | The Broad Institute, Inc. | Crispr enzyme mutations reducing off-target effects |
| AU2016308339A1 (en) | 2015-08-18 | 2018-04-12 | Baylor College Of Medicine | Methods and compositions for altering function and structure of chromatin loops and/or domains |
| US12241053B2 (en) | 2015-10-09 | 2025-03-04 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
| CN116814590A (zh) | 2015-10-22 | 2023-09-29 | 布罗德研究所有限公司 | Vi-b型crispr酶和系统 |
| US11492670B2 (en) | 2015-10-27 | 2022-11-08 | The Broad Institute Inc. | Compositions and methods for targeting cancer-specific sequence variations |
| WO2017075465A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3 |
| WO2017075451A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1 |
| WO2017075478A2 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures |
| WO2017106657A1 (en) | 2015-12-18 | 2017-06-22 | The Broad Institute Inc. | Novel crispr enzymes and systems |
| EP3445853A1 (en) | 2016-04-19 | 2019-02-27 | The Broad Institute, Inc. | Cpf1 complexes with reduced indel activity |
| KR20260004568A (ko) | 2016-04-19 | 2026-01-08 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신규한 crispr 효소 및 시스템 |
| CA3026110A1 (en) | 2016-04-19 | 2017-11-02 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
| AU2017283713B2 (en) | 2016-06-17 | 2021-04-08 | Massachusetts Institute Of Technology | Type VI CRISPR orthologs and systems |
| GB201610867D0 (en) | 2016-06-22 | 2016-08-03 | King S College London | Crystalline forms of a therapeutic compound and processes for their preparation |
| WO2018005873A1 (en) | 2016-06-29 | 2018-01-04 | The Broad Institute Inc. | Crispr-cas systems having destabilization domain |
| US11352647B2 (en) | 2016-08-17 | 2022-06-07 | The Broad Institute, Inc. | Crispr enzymes and systems |
| WO2018035387A1 (en) | 2016-08-17 | 2018-02-22 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
| US20190262399A1 (en) | 2016-09-07 | 2019-08-29 | The Broad Institute, Inc. | Compositions and methods for evaluating and modulating immune responses |
| US12499971B2 (en) | 2016-09-28 | 2025-12-16 | The Broad Institute, Inc. | Systematic screening and mapping of regulatory elements in non-coding genomic regions, methods, compositions, and applications thereof |
| US12447213B2 (en) | 2016-10-07 | 2025-10-21 | The Broad Institute, Inc. | Modulation of novel immune checkpoint targets |
| EA201991809A1 (ru) | 2017-01-30 | 2020-02-05 | КВС ЗААТ СЕ & КО. КГаА | Сцепление матрицы для репарации с эндонуклеазами для геномной инженерии |
| CN110959039B (zh) | 2017-03-15 | 2025-03-14 | 博德研究所 | 新型cas13b直向同源物crispr酶和系统 |
| AU2018251801B2 (en) | 2017-04-12 | 2024-11-07 | Massachusetts Institute Of Technology | Novel type VI CRISPR orthologs and systems |
| WO2018191750A2 (en) | 2017-04-14 | 2018-10-18 | The Broad Institute Inc. | Novel delivery of large payloads |
| US11591601B2 (en) | 2017-05-05 | 2023-02-28 | The Broad Institute, Inc. | Methods for identification and modification of lncRNA associated with target genotypes and phenotypes |
| EP3625342B1 (en) | 2017-05-18 | 2022-08-24 | The Broad Institute, Inc. | Systems, methods, and compositions for targeted nucleic acid editing |
| WO2019010422A1 (en) | 2017-07-07 | 2019-01-10 | The Broad Institute, Inc. | ANTIVIRAL THERAPY BASED ON THE CRISPR SYSTEM |
| KR102338449B1 (ko) | 2017-09-21 | 2021-12-10 | 더 브로드 인스티튜트, 인코퍼레이티드 | 표적화된 핵산 편집을 위한 시스템, 방법, 및 조성물 |
| WO2019071054A1 (en) | 2017-10-04 | 2019-04-11 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR MODIFYING THE FUNCTION AND STRUCTURE OF BUCKLES AND / OR CHROMATIN DOMAINS |
| US12227742B2 (en) | 2017-10-23 | 2025-02-18 | The Broad Institute, Inc. | Nucleic acid modifiers |
| US11547614B2 (en) | 2017-10-31 | 2023-01-10 | The Broad Institute, Inc. | Methods and compositions for studying cell evolution |
| WO2019094983A1 (en) | 2017-11-13 | 2019-05-16 | The Broad Institute, Inc. | Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway |
| WO2019094984A1 (en) | 2017-11-13 | 2019-05-16 | The Broad Institute, Inc. | Methods for determining spatial and temporal gene expression dynamics during adult neurogenesis in single cells |
| US20230193242A1 (en) | 2017-12-22 | 2023-06-22 | The Broad Institute, Inc. | Cas12b systems, methods, and compositions for targeted dna base editing |
| US10968257B2 (en) | 2018-04-03 | 2021-04-06 | The Broad Institute, Inc. | Target recognition motifs and uses thereof |
| EP3830256A2 (en) | 2018-07-31 | 2021-06-09 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
| CA3106035A1 (en) | 2018-08-07 | 2020-02-13 | The Broad Institute, Inc. | Cas12b enzymes and systems |
| WO2020041380A1 (en) | 2018-08-20 | 2020-02-27 | The Broad Institute, Inc. | Methods and compositions for optochemical control of crispr-cas9 |
| WO2020131862A1 (en) | 2018-12-17 | 2020-06-25 | The Broad Institute, Inc. | Crispr-associated transposase systems and methods of use thereof |
| US12215382B2 (en) | 2019-03-01 | 2025-02-04 | The General Hospital Corporation | Liver protective MARC variants and uses thereof |
| US12534714B2 (en) | 2019-03-18 | 2026-01-27 | The Broad Institute, Inc. | Type VII CRISPR proteins and systems |
| US20220220469A1 (en) | 2019-05-20 | 2022-07-14 | The Broad Institute, Inc. | Non-class i multi-component nucleic acid targeting systems |
| GB201907647D0 (en) * | 2019-05-30 | 2019-07-17 | King S College London | Therapeutic methods |
| US12297426B2 (en) | 2019-10-01 | 2025-05-13 | The Broad Institute, Inc. | DNA damage response signature guided rational design of CRISPR-based systems and therapies |
| AU2023250649A1 (en) | 2022-04-04 | 2024-11-14 | The Regents Of The University Of California | Genetic complementation compositions and methods |
| WO2025072383A1 (en) | 2023-09-25 | 2025-04-03 | The Broad Institute, Inc. | Viral open reading frames, uses thereof, and methods of detecting the same |
| WO2025097055A2 (en) | 2023-11-02 | 2025-05-08 | The Broad Institute, Inc. | Compositions and methods of use of t cells in immunotherapy |
| WO2025129158A1 (en) | 2023-12-15 | 2025-06-19 | The Broad Institute, Inc. | Engineered arc delivery vesicles and uses thereof |
| WO2025250808A1 (en) | 2024-05-29 | 2025-12-04 | The Brigham And Women’S Hospital, Inc. | Anti-crispr delivery compositions and methods |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| EP0096910B1 (en) | 1982-05-19 | 1989-04-19 | Unilever N.V. | Yeast of the genus kluyveromyces modified for the expression of preprothaumatin or its various allelic and modified forms or their maturation forms |
| NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
| DE3480411D1 (en) | 1983-07-06 | 1989-12-14 | Gist Brocades Nv | Molecular cloning and expression in industrial microorganism species |
| US4885249A (en) | 1984-12-05 | 1989-12-05 | Allelix, Inc. | Aspergillus niger transformation system |
| ATE253119T1 (de) | 1985-04-15 | 2003-11-15 | Dsm Ip Assets Bv | Verwendung des glucoamylasepromotors aus apergillus |
| IL83192A (en) | 1986-07-18 | 1992-11-15 | Gist Brocades Nv | Method for the preparation of proteins with factor viii activity by microbial host cells;expression vectors,host cells,antibodies |
| US4808630A (en) * | 1987-01-16 | 1989-02-28 | United States Of America | Method of treating psychotic illnesses |
| HU201870B (en) * | 1987-01-16 | 1991-01-28 | Us Health | Process for producing pharmaceutical compositions containing isoretinoin as active component |
| ZA885536B (en) | 1987-07-28 | 1989-04-26 | Gist Brocades Nv | Kluyveromyces as a host strain |
| KR100225087B1 (ko) | 1990-03-23 | 1999-10-15 | 한스 발터라벤 | 피타아제의 식물내 발현 |
| EP0812354A2 (en) * | 1995-01-23 | 1997-12-17 | Ligand Pharmaceuticals, Inc. | HUMAN RETINOID X RECEPTOR - GAMMA (hRXR-GAMMA) |
| IT1276459B1 (it) * | 1995-06-30 | 1997-10-31 | Khodor Ammar | Composizioni cosmetiche con proprieta' antimicotiche, efficaci contro la psoriasi e la caduta dei capelli e metodo cosmetico per la |
| FR2739557B1 (fr) * | 1995-10-09 | 1997-11-14 | Cird Galderma | Utilisation d'un ligand agoniste specifique rar-gamma |
| US5965606A (en) * | 1995-12-29 | 1999-10-12 | Allergan Sales, Inc. | Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity |
| AU6897498A (en) | 1997-04-25 | 1998-11-24 | American Home Products Corporation | Human neuronal cell line |
| EP1027059A2 (en) * | 1997-10-27 | 2000-08-16 | Curis, Inc. | Enhancement of morphogen activity |
-
1999
- 1999-03-31 GB GBGB9907461.9A patent/GB9907461D0/en not_active Ceased
-
2000
- 2000-03-30 CN CNB008080887A patent/CN100350970C/zh not_active Expired - Fee Related
- 2000-03-30 GB GB0123381A patent/GB2365772A/en not_active Withdrawn
- 2000-03-30 KR KR1020017012263A patent/KR20010104401A/ko not_active Withdrawn
- 2000-03-30 AT AT00918991T patent/ATE342728T1/de not_active IP Right Cessation
- 2000-03-30 AU AU39755/00A patent/AU770394B2/en not_active Ceased
- 2000-03-30 EP EP00918991A patent/EP1180039B1/en not_active Expired - Lifetime
- 2000-03-30 CA CA002369009A patent/CA2369009A1/en not_active Abandoned
- 2000-03-30 DE DE60031396T patent/DE60031396T2/de not_active Expired - Fee Related
- 2000-03-30 WO PCT/GB2000/001211 patent/WO2000057900A2/en not_active Ceased
- 2000-03-30 EP EP06076367A patent/EP1762243A1/en not_active Withdrawn
- 2000-03-30 JP JP2000607650A patent/JP2002540164A/ja active Pending
-
2006
- 2006-09-25 US US11/526,458 patent/US20070054961A1/en not_active Abandoned
-
2009
- 2009-09-30 US US12/570,659 patent/US20100317109A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1180039A2 (en) | 2002-02-20 |
| CN100350970C (zh) | 2007-11-28 |
| US20100317109A1 (en) | 2010-12-16 |
| WO2000057900A3 (en) | 2001-02-15 |
| DE60031396D1 (de) | 2006-11-30 |
| CN1355706A (zh) | 2002-06-26 |
| EP1180039B1 (en) | 2006-10-18 |
| DE60031396T2 (de) | 2007-08-30 |
| GB0123381D0 (en) | 2001-11-21 |
| GB2365772A (en) | 2002-02-27 |
| US20070054961A1 (en) | 2007-03-08 |
| AU3975500A (en) | 2000-10-16 |
| WO2000057900A2 (en) | 2000-10-05 |
| KR20010104401A (ko) | 2001-11-26 |
| JP2002540164A (ja) | 2002-11-26 |
| EP1762243A1 (en) | 2007-03-14 |
| CA2369009A1 (en) | 2000-10-05 |
| AU770394B2 (en) | 2004-02-19 |
| GB9907461D0 (en) | 1999-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60031396D1 (de) | Zubereitung zur behandlung von einer neurologischen erkrankung | |
| DE69829921D1 (de) | Vorrichtung zur Behandlung von Körpergewebe | |
| ATE472325T1 (de) | Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen | |
| DE69903543D1 (de) | Formulierungen zur behandlung von magen-speiseröhren reflux | |
| DE60124302D1 (de) | Thiazolderivate zur behandlung von ppar-lierte krankheiten | |
| DE60019556D1 (de) | 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit | |
| ATE271038T1 (de) | 4-phenylpiperidine zur behandlung von prutitischen hauterkrankungen | |
| ATE308997T1 (de) | Mittel zur behandlung von erkrankungen der speiseröhre | |
| DE60019555D1 (de) | 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit | |
| DE69939058D1 (de) | Vorrichtung zur behandlung von peripheren gefässerkrankungen | |
| ATE305306T1 (de) | Reboxetin zur behandlung von peripheren neuropathien | |
| DE60114808D1 (de) | Oberflächenbehandlung von medizinischer vorrichtung | |
| DE60023128D1 (de) | Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen | |
| DE60028863D1 (de) | Elektrochirurgisches Handstück zur Behandlung von Gewebe | |
| DE69936335D1 (de) | Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen | |
| ATA76995A (de) | Stabiles präparat zur behandlung von blutgerinnungsstörungen | |
| ATE292134T1 (de) | Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien | |
| DE60029033D1 (de) | Verfahren zur Behandlung von Tissuepapier | |
| DE60136477D1 (de) | Retinoide zur behandlung von emphysem | |
| DE50013843D1 (de) | Arzneimittel zur behandlung von darmerkrankungen | |
| DE69910202D1 (de) | EGR-1 zur Herstellung eines Medikamentes zur Behandlung von Wunden | |
| DE69420229D1 (de) | Pharmazeutische Zusammensetzung zur Behandlung von AIDS | |
| DE69822297D1 (de) | Triptolid-derivate geeignet zur behandlung von autoimmunkrankheiten | |
| DE69913380D1 (de) | Zusammensetzung zur behandlung von periodontalen erkrankungen | |
| ATE330938T1 (de) | Disulfid-derivate verwendbar zur behandlung von allergischen erkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1180039 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |